Skip to main content
NCBI home page
The Western Journal of Medicine logoLink to The Western Journal of Medicine
. 1982 Oct;137(4):273–277.

Recent Progress in the Treatment of Epithelial Ovarian Malignancy

Jonathan S Berek 1, Neville F Hacker 1, Leo D Lagasse 1
PMCID: PMC1274103  PMID: 7179943

Abstract

Improved surgical and chemotherapeutic management has ensured that more than half the patients with advanced ovarian cancer will be clinically free of disease shortly after treatment begins. Aggressive cytoreductive surgical treatment and combination cytotoxic chemotherapy have appreciably prolonged survival and have induced cures in some women with metastatic disease. An increasing number of women are being seen with small residual disease at second-look laparotomy, and intraperitoneal administration of chemotherapeutic and immunotherapeutic agents is being investigated for these patients. Specific immunotherapies, including monoclonal antibodies raised against patients' own tumor cells, are also being investigated. During the next five years we may see significant improvement in the cure rate for this disease.

Full text

PDF
273

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bast R. C., Jr, Feeney M., Lazarus H., Nadler L. M., Colvin R. B., Knapp R. C. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981 Nov;68(5):1331–1337. doi: 10.1172/JCI110380. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bast R. C., Jr, Knapp R. C., Mitchell A. K., Thurston J. G., Tucker R. W., Schlossman S. F. Immunotherapy of a murine ovarian carcinoma with Corynebacterium parvum and specific heteroantiserum. I. Activation of peritoneal cells to mediate antibody-dependent cytotoxicity. J Immunol. 1979 Nov;123(5):1945–1951. [PubMed] [Google Scholar]
  3. Berek J. S., Griffiths C. T., Leventhal J. M. Laparoscopy for second-look evaluation in ovarian cancer. Obstet Gynecol. 1981 Aug;58(2):192–198. [PubMed] [Google Scholar]
  4. Berek J. S., Hacker N. F., Lagasse L. D., Leuchter R. S. Lower urinary tract resection as part of cytoreductive surgery for ovarian cancer. Gynecol Oncol. 1982 Feb;13(1):87–92. doi: 10.1016/0090-8258(82)90012-9. [DOI] [PubMed] [Google Scholar]
  5. Castaldo T. W., Petrilli E. S., Ballon S. C., Lagasse L. D. Intestinal operations in patients with ovarian carcinoma. Am J Obstet Gynecol. 1981 Jan;139(1):80–84. doi: 10.1016/0002-9378(81)90416-6. [DOI] [PubMed] [Google Scholar]
  6. Cramer D. W., Cutler S. J. Incidence and histopathology of malignancies of the female genital organs in the United States. Am J Obstet Gynecol. 1974 Feb 15;118(4):443–460. doi: 10.1016/s0002-9378(16)33683-3. [DOI] [PubMed] [Google Scholar]
  7. Cutler S. J., Myers M. H., White P. L. Who are we missing and why? Cancer. 1976 Jan;37(1 Suppl):421–425. doi: 10.1002/1097-0142(197601)37:1+<421::aid-cncr2820370703>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  8. Dembo A. J., Bush R. S., Beale F. A., Bean H. A., Pringle J. F., Sturgeon J. F. The Princess Margaret Hospital study of ovarian cancer: stages I, II, and asymptomatic III presentations. Cancer Treat Rep. 1979 Feb;63(2):249–254. [PubMed] [Google Scholar]
  9. Griffiths C. T., Fuller A. F. Intensive surgical and chemotherapeutic management of advanced ovarian cancer. Surg Clin North Am. 1978 Feb;58(1):131–142. doi: 10.1016/s0039-6109(16)41440-4. [DOI] [PubMed] [Google Scholar]
  10. Köhler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975 Aug 7;256(5517):495–497. doi: 10.1038/256495a0. [DOI] [PubMed] [Google Scholar]
  11. Lagasse L. D., Pretorius R. G., Petrilli E. S., Ford L. C., Hoeschele J., Kean C. The metabolism of cis-dichlorodiammineplatinum (II): distribution, clearance, and toxicity. Am J Obstet Gynecol. 1981 Apr 1;139(7):791–798. doi: 10.1016/0002-9378(81)90545-7. [DOI] [PubMed] [Google Scholar]
  13. Reimer R. R., Hoover R., Fraumeni J. F., Jr, Young R. C. Acute leukemia after alkylating-agent therapy of ovarian cancer. N Engl J Med. 1977 Jul 28;297(4):177–181. doi: 10.1056/NEJM197707282970402. [DOI] [PubMed] [Google Scholar]
  14. Rosenshein N. B., Leichner P. K., Vogelsang G. Radiocolloids in the treatment of ovarian cancer. Obstet Gynecol Surv. 1979 Sep;34(9):708–720. doi: 10.1097/00006254-197909000-00028. [DOI] [PubMed] [Google Scholar]
  15. Salmon S. E., Hamburger A. W., Soehnlen B., Durie B. G., Alberts D. S., Moon T. E. Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. N Engl J Med. 1978 Jun 15;298(24):1321–1327. doi: 10.1056/NEJM197806152982401. [DOI] [PubMed] [Google Scholar]
  16. Schwartz P. E., Smith J. P. Second-look operations in ovarian cancer. Am J Obstet Gynecol. 1980 Dec 15;138(8):1124–1130. doi: 10.1016/s0002-9378(16)32778-8. [DOI] [PubMed] [Google Scholar]
  17. Wynder E. L., Dodo H., Barber H. R. Epidemiology of cancer of the ovary. Cancer. 1969 Feb;23(2):352–370. doi: 10.1002/1097-0142(196902)23:2<352::aid-cncr2820230212>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]
  18. Young R. C., Chabner B. A., Hubbard S. P., Fisher R. I., Bender R. A., Anderson T., Simon R. M., Canellos G. P., DeVita V. T., Jr Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. N Engl J Med. 1978 Dec 7;299(23):1261–1266. doi: 10.1056/NEJM197812072992301. [DOI] [PubMed] [Google Scholar]

Articles from Western Journal of Medicine are provided here courtesy of BMJ Publishing Group

RESOURCES